INTRODUCTION AND OBJECTIVES: Penile duplex ultrasound (PDU), combined with pharmacologic stimulation of erection, is the gold standard approach to evaluating multiple penile conditions. The utility of PDU is hindered by a lack of standard approaches to performing and interpreting this study. We examined the variability in international practice patterns, technique and interpretation among practitioners who perform PDU.
METHODS: A 30-question electronic survey was distributed to members of the International Society for Sexual Medicine (ISSM). The survey assessed current PDU practice patterns, technique and interpretation. Chi-square test was used to determine association between categorical variables. RESULTS: The survey was completed by 9.5% of all 1996 current ISSM members. Of ISSM members surveyed, 80% reported using PDU, with more North American practitioners utilizing PDU than their European counterparts (94% vs. 69%, p < 0.01). Urologists performed 62% of all PDU studies, and more than 76% were interpreted by a urologist. Although 90% of practitioners reported using their own standardized protocol, extreme variation in technique existed among respondents. Over 10 different pharmacologic mixtures were used to generate erections, and 17% of respondents did not repeat dosing for insufficient erection. Urologists personally performing PDU were more likely to report assessing cavernosal artery flow in appropriate fashion with the probe at the proximal penile shaft (73% vs 40%) and at a 60degree angle (29% vs 5%) compared to urologists who do not perform PDU (p < 0.01). Large differences in PDU diagnostic thresholds were apparent. Only 38% of respondents defined arterial insufficiency with a peak systolic velocity < 25 cm/sec; while 53% of respondents defined venous occlusive disease with an end diastolic velocity > 5 cm/sec. CONCLUSIONS: PDU is used by a greater proportion of North American sexual medicine practitioners than European counterparts. Although most respondents report using a standardized PDU protocol, widespread variation exists among practitioners in terms of both technique and interpretation. This variation prevents comparison of PDU results and may impair accurate diagnosis and appropriate treatment of penile conditions.
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PD45-09 EARLY DETECTION OF CARDIOVASCULAR DISEASE (CVD) RISK IN MEN WITH ERECTILE DYSFUNCTION (ED) IS FACILITATED USING NEXT GENERATION IMMUNODIAGNOSTICS
Amin Herati*, Houston, TX; Peter Butler, Houstson, TX; Alexander Pastuszak, David Skutt, Larry Lipshultz, HOUSTON, TX INTRODUCTION AND OBJECTIVES: Next generation immunodiagnostic assays offer the ability to quantify single-molecule cardiovascular and inflammatory related biomarkers with high sensitivity. It is known that patients with erectile dysfunction (ED) are at a greater risk for CVD. Additional highly predictive testing, however, is needed to distinguish ED patients at the greatest risk of CVD. We sought to characterize clinically relevant biomarkers that associate with poor erectile function.
METHODS: A retrospective review was performed on men with sexual dysfunction presenting to a single academic andrology clinic. Patients who underwent diagnostic evaluation for sexual dysfunction, completed the International Index of Erectile Function (IIEF) questionnaire, and underwent high sensitivity cardiovascular biomarker testing (Singulex, CA, USA) were included. Electronic medical records were reviewed to collect demographic information. Descriptive statistics and the non-parametric Kruskal-Wallis one-way ANOVA were performed.
RESULTS: A total of 56 men were included in the study, with a control group of 24 men with normal erectile function scores on the IIEF, 14 with mild ED, 5 with mild-moderate ED, 4 with moderate ED, and 9 with severe ED. Mean age for the entire cohort was 42.2 years (SD 14.9) and mean age of the controls was 39.2 (SD 12.5). Serum levels of 22 biological markers of cardiovascular risk were assessed. Of these 22, HDL2B and cTn-I were significantly associated with IIEF scores, with higher HDL2B biomarker levels associated with severe ED (p¼0.038) and lower cTn-I levels associated with severe ED (p¼0.040).
CONCLUSIONS: High sensitivity biomarkers of cardiovascular disease, specifically HDL2B and cTn-I, can facilitate early detection of cardiovascular risk in men with ED, corroborating the known relationship between CVD and ED. Further validation of the clinical relevancy of these biomarkers is necessary to confirm the early risk of CVD risk in men with ED. METHODS: ESWT was performed on patients above 18 years old diagnosed with vascular ED all in stable relationships, with SHIM<20. No PDE-5 inhibitors or any other treatment of ED was allowed. Six treatment sessions were applied twice a week in three consecutive weeks using Omnispec Model ED1000. The intensity of shockwaves was predefined by the manufacturer. Patient received 300 shocks to each of the 5 locations: 3 spots along the penile shaft and 2 spots on the penile crus. Follow-up visits were performed in 1 and 3 months after the end of treatment. After the end of the follow-up period patients randomized in sham-control group were invited for open treatment. Urologist from the unblinded team was responsible for changing treatment applicator and sham applicator according to patients' randomization numbers, whereas the blind team performed the procedure and collected all data from patients. RESULTS: In total, 51 men with ED were included in the study at the moment of publication. 34 patients completed the study: 11 in control and 23 in treatment group. Mean age was 44 (25-67) years. Average time of ED was 13 (6-27) months. SHIM score total in both groups before treatment was 16 (12-20); 17 (12-20) in treatment group and 16 (14-20) in control group. The efficacy of treatment was assessed by comparing SHIM score results before and immediately after treatment, 1 month and 3 months after the treatment. During the treatment period there were no adverse events in both groups. All patients received 6 procedures. In total, 34 men completed the SHIM score questionnaire after the end of treatment period. The result in treatment group was 22 (18) (19) (20) (21) (22) (23) (24) (25) . Pairwise comparison demonstrated significant increase of the score (p¼0.001). Control group did not show any significant increase of the SHIM score, neither in total comparison, where it remained at 17 (12-20), nor in pairwise comparison (p¼0.001).
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CONCLUSIONS: First results of the study demonstrate good efficacy and excellent tolerability of ESWT in treatment of erectile dysfunction.
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